Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Ovarian Neoplasms

  Free Subscription


Articles published in Nat Med

Retrieve available abstracts of 8 articles:
HTML format



Single Articles


    August 2020
  1. GRZYMSKI JJ, Elhanan G, Morales Rosado JA, Smith E, et al
    Population genetic screening efficiently identifies carriers of autosomal dominant diseases.
    Nat Med. 2020;26:1235-1239.
    PubMed     Abstract available


  2. BRASTIANOS PK, Lee EQ, Cohen JV, Tolaney SM, et al
    Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis.
    Nat Med. 2020;26:1280-1284.
    PubMed     Abstract available


    June 2020
  3. IZAR B, Tirosh I, Stover EH, Wakiro I, et al
    A single-cell landscape of high-grade serous ovarian cancer.
    Nat Med. 2020 Jun 22. pii: 10.1038/s41591-020-0926.
    PubMed     Abstract available


    April 2019
  4. KOPPER O, de Witte CJ, Lohmussaar K, Valle-Inclan JE, et al
    An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity.
    Nat Med. 2019 Apr 22. pii: 10.1038/s41591-019-0422.
    PubMed     Abstract available


  5. STOWER H
    Lymph removal not tied to positive outcomes.
    Nat Med. 2019;25:541.
    PubMed    


    September 2017
  6. JANOUSKOVA H, El Tekle G, Bellini E, Udeshi ND, et al
    Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors.
    Nat Med. 2017;23:1046-1054.
    PubMed     Abstract available


    June 2017
  7. RICKMAN DS, Beltran H, Demichelis F, Rubin MA, et al
    Biology and evolution of poorly differentiated neuroendocrine tumors.
    Nat Med. 2017;23:1-10.
    PubMed     Abstract available


    April 2017
  8. DAVIES H, Glodzik D, Morganella S, Yates LR, et al
    HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures.
    Nat Med. 2017;23:517-525.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: